Clinical Research Directory
Browse clinical research sites, groups, and studies.
REXULTI Drug General Use-results Survey (Excessive Motor Activity or Physically/Verbally Aggressive Behavior Due to Rapid Changes in Mood, Irritability, and/or Outbursts Associated With Dementia Due to Alzheimer's Disease)
Sponsor: Otsuka Pharmaceutical Co., Ltd.
Summary
The purpose of this study is to evaluate safety of REXULTI in patients under daily clinical settings. In addition, information on efficacy will be collected.
Key Details
Gender
All
Age Range
15 Years - Any
Study Type
OBSERVATIONAL
Enrollment
200
Start Date
2025-04-17
Completion Date
2028-09-23
Last Updated
2025-07-02
Healthy Volunteers
No
Conditions
Interventions
Brexpiprazole (Rexulti)
In general, for adults, start with taking 0.5 mg of brexpirazole at a time, once a day. Then the dose will be increased with an interval of at least one week to 1 mg at a time, once a day. If you have no problem with tolerability and do not show an adequate response, the dose may be increased to 2 mg at a time, once a day, but the increase should be made at intervals of at least one week.
Locations (1)
Pharmacovigilance Department
Osaka, Osaka, Japan